Jen-Yu Wang

Jen-Yu Wang

Auto-generated profile, based on publicly available information

Jen-Yu Wang

School of Medicine, College of Medicine MacKay Medical University New Taipei City Taiwan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Dermatological Science
Verified
Journal Article
Closed access
JWJen-Yu Wang
Jen-Yu Wang
PLPo-Hsuan Lu
Po-Hsuan Lu
Wan-wan LinWan-wan Lin
Wan-wan Lin
YWYu-Hsuan Wei
Yu-Hsuan Wei
LCLing-Ya Chiu
Ling-Ya Chiu
NWNan-Lin Wu
Nan-Lin Wu

7 January 2022 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
PLPo-Hsuan Lu
Po-Hsuan Lu
JWJen-Yu Wang
Jen-Yu Wang
LCLing-Ya Chiu
Ling-Ya Chiu
YHYi-Ting Huang
Yi-Ting Huang
Chi-Feng HungChi-Feng Hung
Chi-Feng Hung
NWNan-Lin Wu
Nan-Lin Wu

1 March 2016 in Dermatologica Sinica
Verified
Journal Article
Open access
YCYi-Chin Chen
Yi-Chin Chen
LFLi-Ching Fang
Li-Ching Fang
JWJen-Yu Wang
Jen-Yu Wang

8 May 2025 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
LFLi-Ching Fang
Li-Ching Fang
JWJen-Yu Wang
Jen-Yu Wang
Respiratory syncytial virus (RSV) infection may induce asthma and allergic sensitisation. RSV immunoprophylaxis can reduce the severity of RSV infections. However, the effects of RSV immunoprophylaxis on allergic sensitisation remains unclear. We aimed to explore effects of palivizumab, an anti-RSV monoclonal antibody on subsequent IgE sensitisation in preterm children aged ≤18 years with asthma or allergic rhinitis. This retrospective study included 854 preterm children who were followed up and diagnosed with asthma or allergic rhinitis before 18 years old from January 1999 to December 2020. Binary logistic regression was used to investigate effects of palivizumab on the development of IgE sensitisation to aeroallergens or food allergens; the model was adjusted for birth weight, gestational age, foetal growth, sex, and delivery method. Palivizumab could decrease risks of aeroallergen sensitisation until 18 years of age, (adjusted odds ratio (aOR) 0.34, 95 % CI 0.17-0.67, p = 0.002) and as well as in those 7 and 12 years of age. Children receiving palivizumab prophylaxis had lower total sIgE levels (p < 0.001) and eosinophil counts (p = 0.038) than those without prophylaxis. Among asthmatic children, those receiving palivizumab had a shorter duration of active asthma (p < 0.001). In allergic rhinitis population, palivizumab prophylaxis required fewer intranasal corticosteroid (p < 0.001). In preterm children with asthma or allergic rhinitis, early palivizumab prophylaxis may protect against future aeroallergen sensitisation before adulthood. Palivizumab prophylaxis could also decrease the duration of active asthma in asthmatic children and intranasal corticosteroid prescriptions in allergic rhinitis population.

18 September 2026 in Experimental Dermatology
Verified
Journal Article
Closed access
PLPo-Hsuan Lu
Po-Hsuan Lu
LCLing‐Ya Chiu
Ling‐Ya Chiu
JWJen‐Yu Wang
Jen‐Yu Wang
PHPa Fan Fan Hsiao
Pa Fan Fan Hsiao
PLPing-Hsun Lu
Ping-Hsun Lu
NWNan‐Lin Wu
Nan‐Lin Wu